Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered paper session - Genitourinary tumours, prostate

2933 - Updated results of GETUG-12, a phase 3 trial of docetaxel-based chemotherapy in high-risk localized prostate cancer, with a 12-year follow-up.

Date

19 Oct 2018

Session

Proffered paper session - Genitourinary tumours, prostate

Presenters

Karim Fizazi

Citation

Annals of Oncology (2018) 29 (suppl_8): viii271-viii302. 10.1093/annonc/mdy284

Authors

K. Fizazi1, A. Carmel2, F. Joly3, R. Delva4, G. Gravis5, F. Rolland6, F. Priou7, J. Ferrero8, N. Houede9, L. Mourey10, C. Theodore11, I. Krakowski12, J. Berdah13, M. Baciuchka Palmaro14, B. Laguerre15, A. Flechon16, A. Ravaud17, M. Brihoum18, S. Culine19, G. Le Teuff2

Author affiliations

  • 1 Cancer Medicine, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 2 Statistics, Gustave Roussy, 94800 - Villejuif/FR
  • 3 Na, GINECO & Centre Francois Baclesse Caen, 14000 - Caen/FR
  • 4 Medical Oncology Department, Centre Paul Papin, 49100 - Angers/FR
  • 5 Medical Oncology, Institute Paoli Calmettes, 13274 - Marseille/FR
  • 6 Medical Oncology, ICO Institut de Cancerologie de l'Ouest René Gauducheau, 44805 - Saint-Herblain/FR
  • 7 Medical Oncology, CHD Vendee - Hopital Les Oudairies, 85925 - La Roche sur Yon/FR
  • 8 Department Of Medical Oncology, Centre Antoine Lacassagne, 6189 - Nice/FR
  • 9 Medical Oncology Departmentical Oncology Department, Institut de cancérologie du Gard, 30029 - Nimes/FR
  • 10 Medical Oncology, Institut Universitaire du Cancer -Toulouse- Oncopole, 31059 - Toulouse/FR
  • 11 Medical Oncology, Hopital Foch, 92151 - Suresnes/FR
  • 12 Medical Oncology & Supportive Care, Institute Bergonié, 33076 - Bordeaux/FR
  • 13 Medical Oncology, Oncovar, Hyeres/FR
  • 14 Medical Oncology, Hopital Nord, 13915 - Marseille/FR
  • 15 Medical Oncology, Centre Eugene - Marquis, 35042 - Rennes/FR
  • 16 Medical Oncology, Centre Léon Bérard, 69008 - Lyon/FR
  • 17 Medical Oncology, CHU Bordeaux Hopital St. André, 33000 - Bordeaux/FR
  • 18 Clinical research, Unicancer, Kremlin-Bicêtre/FR
  • 19 Medical Oncology, Hôpital St. Louis, 75010 - Paris/FR
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2933

Background

GETUG-12 assessed docetaxel-estramustine in patients with high-risk localized prostate cancer: the primary endpoint of relapse-free survival (RFS) was met (adjusted HR: 0.71 [95% CI: 0.54-0.94], p = 0.017) (Lancet Oncol 2015; 16: 787-94). This analysis updates RFS and assesses clinical events for the first time.

Methods

Eligibility included non-pretreated high-risk localized prostate cancer, defined as ≥ 1 of the following: T3-T4, Gleason ≥8, PSA ≥20 ng/mL, pN + (stratification factors). All 413 patients had a staging pelvic lymph node dissection. Patients were randomized to goserelin for 3 years and 4 cycles of docetaxel 70 mg/m2 + estramustine 10 mg/kg/d days 1-5, every 3 weeks (ADT+DE arm) or goserelin alone (ADT arm). Local therapy (radiotherapy: 87%) was administered at 3 months. Outcomes were tested with a pre-specified order (1: RFS, 2: clinical RFS (cRFS), and 3: metastases-free survival (MFS)) by the fixed-sequence method for controlling the family-wise error rate when conducting tests for multiple endpoints. RFS events: biochemical failures, metastases, proven local relapses, use of salvage treatment, and deaths. cRFS events: metastases, proven local relapses, and deaths. MFS events: metastases and deaths.

Results

With a median follow-up of 12 years [95% CI 11.9–12.2], 233 patients (56%) have had an event. RFS was improved in the ADT+DE arm: 12-year RFS rate: 49.4% [42.5%; 56.3%] in the ADT+DE arm vs 36.3% [29.7%; 43.5%] in the ADT arm (adjusted HR: 0.71 [0.55; 0.93], p = 0.01). The median RFS was 11.6 [9.1; NR] and 8.1 [7.3; 9.6] years. cRFS was also significantly improved in the ADT+DE arm (adjusted HR: 0.75 [0.56 ; 1.00]; p = 0.0491); 12-year rates: 58.8% [51.7% ; 65.6%] vs 50.5% [43.4% ; 57.6%]; median cRFS: 13.9 (13.3-14.9) vs 12.5 (9.9-15.3) years. 12-year MFS rates were 62.2% [55.1%; 68.8%] and 55.8% [48.6%; 62.8%] (adjusted HR: 0.81 [0.60; 1.09]. 12-year PC-specific survival rates were 88.2% [82.5%; 92.2%] and 83.9% [77.4%; 88.8%] (adjusted HR: 0.70 [0.40; 1.22]). The 12-year cumulative rates of second cancers (16.4% vs 18.8%) were similar.

Conclusions

Four cycles of docetaxel-based chemotherapy reduces the risk of clinical relapse or death in men with high-risk localized prostate cancer.

Clinical trial identification

NCT00055731.

Legal entity responsible for the study

UNICANCER.

Funding

UNICANCER.

Editorial Acknowledgement

Disclosure

K. Fizazi: Advisory boards, honorarium: Sanofi. F. Joly: Advisory boards: Sanofi. G. Gravis: Travel expense: Sanofi, Janssen, Astellas. L. Mourey: Travel expense, honoraria: Sanofi. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings